A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01254643 |
Recruitment Status :
Completed
First Posted : December 6, 2010
Results First Posted : December 22, 2014
Last Update Posted : November 28, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Papillomavirus Infections | Biological: V503 | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 100 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | A Phase III Open-label, Safety, Tolerability and Immunogenicity Study of a 9-Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 9- to 15-Year-Old Japanese Preadolescent and Adolescent Girls |
Actual Study Start Date : | January 12, 2011 |
Actual Primary Completion Date : | August 10, 2013 |
Actual Study Completion Date : | August 10, 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: All Enrolled
9-valent human papillomavirus (9vHPV) L1 VLP vaccine (V503), 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6.
|
Biological: V503
V503 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 |
- Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine [ Time Frame: 4 weeks post-vaccination 3 (Month 7) ]Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using competitive luminex immunoassay (cLIA). The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.
- Percentage of Participants With an Injection-site Adverse Event (AE) [ Time Frame: up to 5 days after any vaccination ]An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. AEs such as redness, swelling, and pain/tenderness/soreness at the injection site were recorded.
- Percentage of Participants With a Non-Injection Site (Systemic) AE [ Time Frame: up to 15 days after any vaccination ]An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Systemic AEs were those not categorized as injection-site AEs.
- Percentage of Participants With a Vaccine-related AE [ Time Frame: up to 15 days after any vaccination ]An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Adverse experience that is judged by the Investigator to be "definitely related," "probably related," or "possibly related" to the study drug is defined as a vaccine-related AE.
- Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine [ Time Frame: 4 weeks post-vaccination 3 (Month 7) ]Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using cLIA. Titers are reported in milli Merck Units/mL.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 9 Years to 15 Years (Child) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Participant is in good physical health-
- Participant's parent/legal guardian is able to read, understand, and complete the vaccine report card
- Participant's parent/legal guardian agrees to provide a phone number for follow-up purposes
- Participant is not sexually active and does not plan to become sexually active during the time from Day 1 to Month 7 of the study
Exclusion Criteria:
- Participant has a history of severe allergic reaction that required medical intervention
- Participant has thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection
- Participant is pregnant
- Participant intends to donate blood during the time from Day 1 to Month 7 of the study
- Participant is immunocompromised or has been diagnosed as having a congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition.
- Participant has had a splenectomy
- Participant has received any of the following immunosuppressive therapies in the year prior to enrollment: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide (Arava), tumor necrosis factor alpha (TNF-α) antagonists, monoclonal antibody therapies, antilymphocyte sera, or other therapy known to interfere with the immune response.
- Participant has received any immune globulin product or blood-derived product in the three months prior to the Day 1 vaccination, or plans to receive any such product through Month 7 of the study
- Participant has received any inactivated vaccines within 14 days of the Day 1 vaccination or any live vaccines within 28 days of the Day 1 vaccination
- Participant has received a marketed HPV vaccine or has participated in an HPV vaccine clinical trial
- Participant has had a fever (oral temperature ≥37.8°C) within 24 hours of the Day 1 vaccination
- Participant has a history of a positive test for HPV or history of genital warts

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01254643
Study Director: | Medical Director | Merck Sharp & Dohme Corp. |
Responsible Party: | Merck Sharp & Dohme Corp. |
ClinicalTrials.gov Identifier: | NCT01254643 |
Other Study ID Numbers: |
V503-008 |
First Posted: | December 6, 2010 Key Record Dates |
Results First Posted: | December 22, 2014 |
Last Update Posted: | November 28, 2018 |
Last Verified: | October 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf |
URL: | http://engagezone.msd.com/ds_documentation.php |
Papillomavirus vaccines Uterine cervical cancer Human Papilloma Virus infections |
Papillomavirus Infections DNA Virus Infections Virus Diseases Tumor Virus Infections |